New heart valves show promise in 5-Year Follow-Up study

NCT ID NCT05055089

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 172 patients who received either a new-generation biological aortic valve or a traditional one during heart surgery. Researchers tracked survival and valve function over five years to see how the newer valves compare. The goal is to provide real-world data on these newer devices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: new-generation biological aortic valve (rapid deployment or sutureless bioprosthesis)
What this could lead to: If successful, this study could provide evidence that newer aortic valves perform as well or better than traditional ones, potentially guiding future surgical choices.
What could go wrong: This is an observational, retrospective study with a moderate sample size, so results may not be definitive or widely generalizable. No new treatment is being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC VALVE CARDIAC SURGERY ECHOCARDIOGRAPHY MORTALITY

Contacts and locations

Locations

CHU Amiens Nord

Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.